Canada Green Lights Country’s Third Clinical Psilocybin Study
Research
The trial will build on Diamond Therapeutic's previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.
Leave a Reply
Want to join the discussion?Feel free to contribute!